Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer (Q36080684)

12 August 2017

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer (English)

1 reference

12 August 2017

1 reference

J A Foekens

1

1 reference

12 August 2017

H Portengen

2

1 reference

12 August 2017

M P Look

3

1 reference

12 August 2017

W L van Putten

4

1 reference

12 August 2017

B Thirion

5

1 reference

12 August 2017

M Bontenbal

6

1 reference

12 August 2017

J G Klijn

7

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 December 1994

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

70

1 reference

12 August 2017

6

1 reference

12 August 2017

1217-1223

1 reference

Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Cell biological factors associated with the response of breast cancer to systemic treatment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Estrogen receptor mutations in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

pS2 is an independent factor of good prognosis in primary breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Mechanisms of hormone resistance in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Progestin action and progesterone receptor structure in human breast cancer: a review.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Characterisation of a messenger RNA selectively expressed in human breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Prediction of relapse and survival in breast cancer patients by pS2 protein status

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Truncated forms of DNA-binding estrogen receptors in human breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Prognostic factors and treatment decisions in axillary-node-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Predicting Response to Endocrine Therapy in Human Breast Cancer: A Hypothesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Oncogenes homologous to steroid receptors?

11 July 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981080

12 December 2020

pS2 expression and response to hormonal therapy in patients with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981080

12 December 2020

pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981080

12 December 2020

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981080

12 December 2020

pS2 protein and steroid hormone receptors in invasive breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981080

12 December 2020

Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981080

12 December 2020

Effect of adjuvant systemic therapy on response to treatment after relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981080

12 December 2020

Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981080

12 December 2020

The value of estrogen and progesterone receptors in the treatment of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7981080

12 December 2020

Identifiers

DOI

10.1038/BJC.1994.476

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

7981080

1 reference